NEWS

AUGUST 20, 2019
Outlook Completes Patient Enrollment for NORSE 1, a Phase 3 Clinical Trial for ONS-5010 in Wet AMD
JULY 16, 2019
Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD

Outlook Therapeutics…

…is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, for various ophthalmic indications..

ABOUT ONS-5010

ONS-5010 is a proprietary ophthalmic formulation of bevacizumab to be administered as an intravitreal injection for the treatment of wet AMD and other retina diseases.